Clyde Frazier's Rea...
Health Care: Drugs
Curis Inc. (CRIS: NASDAQ)
$4.98 -0.12 | -2.35%
02/09/12 - 04:00 PM ET
1.18M / 409.80K
Vol / Avg. Vol:5.15 / 5.10
Open / Prev. Close:4.95 - 5.22
Today's Range:2.70 - 5.65
52 Wk Range:8.97%
Performance YTD:TheStreet Rating:
Portfolios with CRIS
- Portfolio NameUser Type
- Userwjwallace Portfolio
- Contributor5 Stocks to Watch Under $5
- ContributorStocks At New 52-Week Highs...
- ContributorBreakout Stocks Of The Week...
- UserMontana Nugget
- ContributorCancer Drug Stocks to Trade...
- Usermoney II
- Usermoney
- Contributor5 Bargain Biotech Stocks
- Contributor10 Biotech Stocks Expected ...
Latest CRIS Headlines from TheStreet
- FDA Approves Roche, Curis Skin-Cancer Drug 01.30.12 | 11:01 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 5 Stocks to Watch Under $5 12.29.11 | 10:12 am
- 27 Hot Drugs Facing FDA Approval in 2012 12.19.11 | 10:12 am
- 5 Stocks Poised to Break Out 07.22.11 | 02:07 pm
- A Busy Week for Six Biotech Stocks 06.20.11 | 06:06 am
- Curis Inc. Stock Downgraded (CRIS) 05.02.11 | 06:05 pm
- Curis Reaches New 52-Week High (CRIS) 04.27.11 | 09:04 am
- Curis Stock Hits New 52-Week High (CRIS) 04.05.11 | 02:04 pm
- OptionsXpress, Rite Aid: Small-Cap Winners 03.21.11 | 12:03 pm
Press Releases for CRIS
- Curis Announces Collaborator Roche’s Submission Of Marketing Authorization Application For Vismodegib In Advanced Basal Cell Carcinoma - Business Wire 12.22.11 | 07:12 am
- Curis To Present At The Oppenheimer & Company’s 22nd Annual Healthcare Conference - Business Wire 12.06.11 | 07:12 am
- Curis Announces Agreement With The Leukemia & Lymphoma Society To Develop CUDC-907 For Lymphoma And Multiple Myeloma - Business Wire 11.30.11 | 07:11 am
- Curis To Present At Piper Jaffray 23rd Annual Healthcare Conference - Business Wire 11.23.11 | 08:11 am
- Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907 At The 2011 AACR-NCI-EORTC Symposium - Business Wire 11.16.11 | 08:11 am
- Curis Announces FDA Acceptance And Priority Review Of NDA For Vismodegib As Treatment For Advanced Basal Cell Carcinoma - Business Wire 11.09.11 | 01:11 am
- Curis Announces Appointment Of Maurizio Voi, M.D. As Chief Medical And Chief Development Officer - Business Wire 11.08.11 | 07:11 am
- Curis To Present At The Lazard Capital Markets Healthcare Conference - Business Wire 11.07.11 | 04:11 pm
- Curis Reports Third Quarter 2011 Financial Results - Business Wire 10.27.11 | 07:10 am
- Curis To Release Third Quarter 2011 Financial Results And Hold Conference Call On October 27, 2011 - Business Wire 10.20.11 | 08:10 am
Partner Headlines for CRIS
- Rodman & Renshaw Outperform On Curis, Inc. - Benzinga 06.21.11 | 01:06 pm
- Positive Data on Roche's BCC Drug - Analyst Blog - Zacks 06.21.11 | 10:06 am
- Morning Market Movers (CRIS, OXPS, SMIT, TGE) - Benzinga 03.21.11 | 09:03 am
- Zacks #5 Rank Additions for Monday - Tale of the Tape - Zacks 02.14.11 | 09:02 am
- UPDATE 2-Curis says Roche seeks more analysis of cancer drug - Reuters 08.09.10 | 01:08 pm
- UPDATE 4-Curis says cancer drug fails in mid-stage trial - Reuters 06.16.10 | 02:06 pm
- Curis, Roche drug combats children's brain tumors - Reuters 06.05.10 | 09:06 am
- 4 Stocks to Watch at ASCO - Seeking Alpha 06.02.10 | 07:06 am
- 2 Smallcap Biotech Stocks to Watch - SeekingAlpha.com 04.20.10 | 01:04 am
- CORRECTED - CORRECTED-UPDATE 1-Curis gets milestone payments from Debiopharm - Reuters 02.12.10 | 11:02 am
